SCHEMBL1765031

SCHEMBL1765031

CCOC(=O)c1cc(-c2ccc(F)c(Cl)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.60
CA9 Q16790 3/20 0.54
FAAH O00519 2/20 0.52
RPA1 P27694 6/20 0.50
PPP1CA P62136 2/20 0.50
MGLL Q99685 1/20 0.49
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MARS1 P56192 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765306 0.93 CHRNA7 (0.55) CHRNA7CA9FAAHPPP1CAMGLL
SCHEMBL1764980 0.91 CHRNA7 (0.53) CHRNA7CA9FAAHRPA1MGLL
SCHEMBL1526084 0.89 CHRNA7 (0.54) CHRNA7CA9FAAHRPA1PPP1CA
SCHEMBL1765431 0.89 CHRNA7 (0.52) CHRNA7CA9FAAHRPA1PPP1CA
SCHEMBL1764884 0.89 CHRNA7 (0.53) CHRNA7CA9FAAHRPA1PPP1CA
SCHEMBL1765261 0.88 FAAH (0.56) CHRNA7CA9FAAHRPA1MGLL
SCHEMBL1765367 0.87 CHRNA7 (0.50) CHRNA7CA9FAAHRPA1PPP1CA
SCHEMBL1764943 0.87 FAAH (0.53) CHRNA7CA9FAAHRPA1MGLL
SCHEMBL1765280 0.87 CHRNA7 (0.50) CHRNA7CA9FAAHRPA1MGLL
SCHEMBL1765484 0.87 CHRNA7 (0.52) CHRNA7CA9FAAHRPA1PPP1CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO CHRNA7 3365/4885CA9 4825/4885FAAH 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.